Replimune to Resubmit Melanoma Drug for FDA Approval Following Leadership Changes
Replimune is set to resubmit its melanoma drug for FDA review following a leadership change at the agency, which previously rejected the treatment twice. This development is significant as it may open new avenues for patients with limited treatment options and has already led to a substantial increase in Replimune's stock price.